List of Excipients in Branded Drug NALOCET

Generic Drugs Containing NALOCET

Company	Ingredient	NDC	Excipient
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	CELLULOSE, MICROCRYSTALLINE
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	CROSCARMELLOSE SODIUM
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	CROSPOVIDONE
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	FD&C BLUE NO. 1
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	POVIDONE
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	SILICON DIOXIDE
Forte Bio-Pharma LLC	oxycodone and acetaminophen	72245-193	STARCH, CORN

What are the Most Frequently-Used Excipients in NALOCET?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
1	FD&C BLUE NO. 1
1	POVIDONE
1	SILICON DIOXIDE
1	STARCH, CORN

NALOCET Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

NALOCET is an immediate-release, Schedule II combination tablet containing oxycodone hydrochloride and acetaminophen. Its commercial differentiation is limited by the mature status of the active ingredients, the availability of generic oxycodone/acetaminophen products, opioid-control requirements, and acetaminophen safety limits. The strongest excipient opportunities are therefore in manufacturing efficiency, tablet robustness, swallowability, supply-chain resilience, patient-specific formulations, and evidence-backed abuse-deterrent technology rather than in basic composition-of-matter protection.[1]

What is NALOCET and how is it formulated?

NALOCET contains oxycodone hydrochloride and acetaminophen in four immediate-release strengths:

Strength	Oxycodone HCl	Acetaminophen	Dosage form
Low strength	2.5 mg	300 mg	Immediate-release tablet
Standard strength	5 mg	300 mg	Immediate-release tablet
Higher strength	7.5 mg	300 mg	Immediate-release tablet
Maximum listed strength	10 mg	300 mg	Immediate-release tablet

The product is administered orally for pain severe enough to require an opioid analgesic when alternative treatments are inadequate. The fixed acetaminophen content creates an important commercial constraint: dose escalation increases oxycodone exposure while also increasing cumulative acetaminophen exposure.[1]

The label identifies a conventional tablet excipient platform that includes common diluents, binders, disintegrants, glidants, lubricants and coating materials. Public labeling identifies ingredients such as lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, sodium starch glycolate, magnesium stearate, stearic acid, colloidal silicon dioxide, hypromellose and talc, with colorants varying by strength.[1]

What excipient functions are important in NALOCET?

The current formulation architecture is consistent with immediate-release opioid tablet requirements:

Excipient function	Likely commercial purpose
Lactose monohydrate and microcrystalline cellulose	Tablet bulk, compressibility and dose uniformity
Povidone	Granulation or dry-binding performance
Crospovidone and sodium starch glycolate	Rapid tablet breakup after ingestion
Colloidal silicon dioxide	Powder flow and content uniformity
Magnesium stearate and stearic acid	Ejection and lubrication
Hypromellose and talc	Film-coating structure and processing
Colorants	Strength identification and product differentiation

For a low-dose oxycodone component combined with 300 mg of acetaminophen, content uniformity is a critical development attribute. The excipient system must prevent segregation of the low-dose opioid during blending, transfer and compression. This favors excipients with predictable particle-size distribution, strong flow properties and established performance in direct compression or low-shear granulation.

What excipient strategy best supports NALOCET manufacturing?

The optimal near-term strategy is a robust immediate-release platform rather than a complex modified-release system. The formulation should prioritize:

1. Low blend segregation.
2. Short disintegration time.
3. Adequate mechanical strength.
4. Low friability during packaging and transport.
5. Consistent dissolution across strengths.
6. Reduced sensitivity to magnesium-stearate over-lubrication.
7. Reliable performance at commercial scale.

How can excipients reduce manufacturing cost?

A manufacturer can reduce cost through a common-platform formulation across all strengths. Using the same excipient backbone allows shared:

• Raw-material specifications.
• Granulation or blending parameters.
• Compression tooling.
• Coating process.
• Stability protocol.
• In-process control strategy.
• Packaging configuration.

The key development target is a formulation that tolerates ordinary variation in powder moisture, particle size and lubricant mixing time. A highly sensitive blend can generate commercial losses through content-uniformity failures, capping, sticking or dissolution drift.

Direct compression can lower processing costs, but it requires excipients with strong flow and compactability. Roller compaction or wet granulation may provide better control when the oxycodone fraction is low or when powder segregation is observed. The commercial choice depends on equipment, scale and the ability to maintain uniformity across all strengths.

Which excipients can improve tablet robustness?

Microcrystalline cellulose, silicified microcrystalline cellulose, coprocessed mannitol and selected spray-dried lactose grades can improve compactability and reduce tablet defects. The substitution must be assessed against:

• Dissolution profile.
• Tablet hardness.
• Disintegration.
• Moisture uptake.
• Stability-indicating impurities.
• Bioequivalence risk.
• Supplier qualification requirements.

A switch from lactose-based filler systems to mannitol or anhydrous dibasic calcium phosphate could create differentiated products, but the change may also alter compression force, disintegration and dissolution. For a mature immediate-release product, the commercial value lies in solving a defined manufacturing or patient problem, not in changing excipients without a measurable benefit.

What formulations are protected by NALOCET patents?

NALOCET does not obtain broad exclusivity from the old oxycodone/acetaminophen combination itself. Oxycodone and acetaminophen are established active ingredients, and multiple generic products exist in the United States.

The relevant protection categories are narrower:

Protection category	Relevance to NALOCET
Composition-of-matter patents	Not a meaningful current protection route for the established actives
Fixed-dose combination patents	Potentially relevant only if a novel ratio, dosage form or formulation is claimed
Formulation patents	Could protect excipient combinations, particle engineering, coating or release behavior
Method-of-use patents	Could cover a specific patient population or treatment method, subject to enforceability
Abuse-deterrent patents	Could cover mechanical, chemical or pharmacokinetic barriers to misuse
Manufacturing patents	Could protect continuous processing, granulation, compression or impurity control
Trademark rights	Protect the NALOCET brand, not the underlying active ingredients

A commercial assessment should distinguish NALOCET-specific rights from patents listed for other oxycodone/acetaminophen products. Orange Book status is product-specific and should be reviewed by application number and listed patent.[2]

What is the Orange Book status of NALOCET?

The FDA Orange Book records approved drug applications, therapeutic-equivalence information, patent listings and regulatory exclusivity. A brand product’s commercial position depends on whether it is the reference listed drug, an approved NDA product without significant exclusivity, or a product supported by a different regulatory pathway.[2]

For NALOCET, the principal business conclusion is that excipient differentiation is unlikely to create a long period of regulatory exclusivity by itself. A new product relying on the same active ingredients would generally need to pursue one of the following paths:

• An ANDA demonstrating bioequivalence to a suitable reference product.
• A 505(b)(2) application supported by bridging data and a differentiated formulation or use.
• A new NDA for a materially novel formulation, delivery system or abuse-deterrent design.

A conventional excipient substitution generally does not create a strong standalone regulatory moat. It can still support an ANDA, improve manufacturing economics or provide a basis for a product-specific 505(b)(2) program when the formulation produces clinically or operationally meaningful differences.

When does NALOCET lose exclusivity?

The core oxycodone/acetaminophen combination is already exposed to generic competition. The relevant exclusivity question is therefore not a single future loss date but the remaining commercial value of the NALOCET brand.

Exclusivity type	NALOCET commercial implication
Active-ingredient patent	Mature and not the principal barrier
New-drug exclusivity	Any original period is not the current market barrier
Orphan exclusivity	Not applicable to routine acute pain use
Pediatric exclusivity	No basis to assume an active benefit without a specific FDA award
Formulation patent	Must be assessed from current Orange Book listings
Trademark exclusivity	Continues while the mark is maintained, but does not block generics

The practical loss-of-exclusivity risk is ongoing generic substitution, payer pressure and procurement displacement. Brand retention depends on availability, contract pricing, prescriber familiarity, packaging, supply reliability and any clinically supported formulation advantage.

What generic entry risks exist for NALOCET?

Generic entry risk is high because the product is an immediate-release oral tablet with established active ingredients and a well-understood pharmacokinetic profile. Potential entrants can compete through:

• Conventional oxycodone/acetaminophen tablets.
• Multiple strengths.
• Authorized-generic arrangements.
• Institutional supply contracts.
• Pharmacy substitution.
• Wholesale and group-purchasing agreements.

An ANDA applicant normally does not need to copy every excipient. It must demonstrate pharmaceutical equivalence and bioequivalence while meeting quality, impurity, dissolution and stability requirements.[3]

Excipient-related barriers can still slow entry when the product has:

• A narrow content-uniformity window.
• A difficult low-dose blend.
• A sensitive dissolution profile.
• A unique coating or imprint system.
• A supplier-dependent excipient.
• A complex manufacturing process.
• A difficult-to-control impurity profile.

These are manufacturing barriers, not necessarily patent barriers. They can provide time and cost advantages but rarely produce durable exclusivity without claims covering the process or formulation.

Which companies are challenging NALOCET?

The principal competitive threat comes from manufacturers of generic oxycodone hydrochloride/acetaminophen tablets rather than from biosimilar developers. Relevant competitive groups include large generic companies, specialty pharmaceutical manufacturers and contract manufacturers with Schedule II handling capability.

A company-specific Paragraph IV analysis requires current ANDA notices, Orange Book records and federal court filings. No biosimilar pathway applies because NALOCET is a small-molecule drug, not a biologic. The relevant challenges are ANDA filings, Paragraph IV certifications, declaratory actions and commercial generic launches.[2,4]

How do Paragraph IV risks affect an excipient strategy?

A formulation patent supported by an excipient combination may be challenged on:

• Anticipation by earlier tablet formulations.
• Obviousness based on routine excipient selection.
• Lack of unexpected dissolution or stability results.
• Lack of enablement across the full claim scope.
• Inadequate written description.
• Non-infringement because the generic uses different excipients.

A patent strategy should focus on measurable technical effects, such as a defined dissolution range, improved content uniformity, reduced degradation, lower friability or an abuse-deterrent property. Broad claims to ordinary excipients in conventional quantities are vulnerable.

What commercial opportunities exist for NALOCET excipients?

Can a lactose-free or dye-free NALOCET create market differentiation?

Yes, but the opportunity is niche. A lactose-free formulation could address patients with lactose intolerance or avoid lactose-related manufacturing concerns. A dye-free version could appeal to institutional formularies and patients seeking reduced excipient exposure.

These products would need validated stability, dissolution and bioequivalence support. The commercial opportunity is stronger if the reformulation also improves supply continuity or simplifies the inactive-ingredient declaration.

Can a low-swallowing-burden formulation compete?

Potentially. Tablet size, coating smoothness, friability and mouthfeel can influence adherence, particularly for older adults and patients taking multiple medicines. A smaller tablet or an orally disintegrating product could provide differentiation, but an orally disintegrating oxycodone product creates higher control, diversion and abuse-deterrence concerns.

A 505(b)(2) strategy could be considered for a genuinely differentiated dosage form. The value would depend on clinical usability, payer acceptance, abuse-risk controls and the ability to secure enforceable claims.

Is an abuse-deterrent NALOCET formulation commercially attractive?

An abuse-deterrent formulation could support premium positioning, institutional contracting and possible labeling differentiation if it satisfies FDA guidance and earns an abuse-deterrent label.[5] Candidate technologies include:

• Polymer matrices that resist crushing.
• Gelling systems that limit syringeability.
• Aversion agents.
• Chemical barriers to extraction.
• Physical barriers to manipulation.
• Pharmacokinetic designs that reduce rapid opioid release.

The development burden is high. In vitro manipulation studies, pharmacokinetic studies and human abuse-potential data may be required. An abuse-deterrent formulation does not eliminate abuse or addiction risk, and the FDA does not consider the technology abuse-proof.[5]

Can excipient suppliers capture value without owning the drug?

Yes. Suppliers can sell differentiated excipient systems rather than individual materials. Commercial targets include:

• Coprocessed direct-compression platforms.
• Low-moisture fillers for improved stability.
• High-efficiency disintegrant systems.
• Lubricant systems that reduce dissolution impact.
• Low-segregation excipient blends.
• Functional coating systems.
• Excipient packages designed for continuous manufacturing.

The strongest supplier proposition is a validated, scale-ready formulation package that reduces development time and manufacturing failures. Supplier value increases when the package is supported by regulatory documentation, global compendial compliance, extractables and leachables data, and dual-source availability.

What manufacturing and intellectual-property barriers affect NALOCET?

The principal technical barriers are low-dose uniformity, controlled-substance compliance, acetaminophen impurity control, tablet robustness and supply security.

Controlled-substance manufacturing requires secure handling, inventory reconciliation and compliance with Drug Enforcement Administration requirements. The formulation also must control acetaminophen degradation products and maintain dissolution throughout shelf life. Packaging may require tamper-evident features and restricted distribution controls.

Geographic protection is limited for a conventional formulation. U.S. FDA approval, European authorization, Canadian approval and other national registrations are separate regulatory assets. A formulation patent can provide country-specific rights, but excipient patents must be assessed jurisdiction by jurisdiction. The commercial value of a global excipient platform depends on whether the same composition, process and specifications can be defended across major markets.

How does NALOCET compare with competing opioid-acetaminophen products?

Product category	Formulation profile	Competitive position
NALOCET	Immediate-release oxycodone/acetaminophen tablet	Brand and supply-chain differentiation
Generic oxycodone/acetaminophen	Immediate-release tablet	Lowest-cost substitution risk
Hydrocodone/acetaminophen	Alternative opioid-acetaminophen combination	Prescriber and formulary substitute
Tramadol/acetaminophen	Different opioid mechanism and risk profile	Alternative for selected pain settings
Non-opioid combinations	NSAID, acetaminophen or multimodal therapy	Important substitution pressure
Abuse-deterrent opioid formulations	Technology-enabled opioid products	Potential premium segment

NALOCET’s most defensible commercial route is a focused formulation or supply advantage. A conventional tablet without a differentiated excipient, packaging, contracting or abuse-deterrent proposition is exposed to price competition.

Key Takeaways

• NALOCET is an immediate-release oxycodone hydrochloride/acetaminophen tablet in 2.5/300, 5/300, 7.5/300 and 10/300 mg strengths.
• Its excipient system is conventional and designed for rapid disintegration, content uniformity, compressibility and coating performance.
• The active ingredients and combination have extensive generic competition, making composition-of-matter exclusivity unavailable as a commercial strategy.
• The most credible excipient opportunities are low-segregation processing, improved tablet robustness, lactose-free or dye-free products, smaller tablets, supply-chain resilience and abuse-deterrent technology.
• A conventional excipient change is unlikely to support meaningful exclusivity without unexpected technical results or a differentiated regulatory pathway.
• Paragraph IV risk is structurally high because generic manufacturers can use different excipients if they demonstrate pharmaceutical equivalence and bioequivalence.
• NALOCET has no biosimilar risk because it is a small-molecule drug.
• The strongest commercial moat would combine a defensible formulation patent, FDA-recognized product differentiation, controlled-substance compliance and reliable institutional supply.

FAQs

Can NALOCET be reformulated with mannitol instead of lactose?

Yes. Mannitol can provide a lactose-free filler platform, but the reformulation would require evaluation of compression, disintegration, dissolution, stability and bioequivalence.

Does an excipient change require a new FDA approval?

The regulatory pathway depends on the extent of the change. A manufacturer may use an approved post-approval supplement for certain manufacturing changes, while a materially differentiated dosage form may require a 505(b)(2) application or new NDA.

Can NALOCET use a co-processed excipient system?

Yes. A co-processed system could improve flow, compactability and low-dose blend uniformity. Its value depends on demonstrated process and product performance.

Would a dye-free NALOCET have patent value?

A dye-free formulation alone is unlikely to create strong patent protection. Patent value would be higher if the formulation also delivered an unexpected stability, dissolution, manufacturability or patient-use benefit.

Can an abuse-deterrent NALOCET obtain premium pricing?

Potentially, but premium pricing would depend on FDA-recognized abuse-deterrent labeling, payer and institutional acceptance, manufacturing cost, abuse-risk evidence and the strength of competing opioid products.

References

1. U.S. Food and Drug Administration. (n.d.). NALOCET (oxycodone hydrochloride and acetaminophen) tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format.
4. U.S. Food and Drug Administration. (n.d.). Paragraph IV patent certifications and 30-month stays.
5. U.S. Food and Drug Administration. (2015). General principles for evaluating abuse deterrence of generic solid oral opioid drug products.